We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+49.06%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$459M
AUM Growth
+$82.8M
Cap. Flow
-$20.4M
Cap. Flow %
-4.45%
Top 10 Hldgs %
57.01%
Holding
59
New
13
Increased
17
Reduced
15
Closed
7

Top Buys

Rank Stock Value
1
LYEL icon
Lyell Immunopharma
LYEL
+$7.18M
2
CMPX icon
Compass Therapeutics
CMPX
+$5.48M
3
RVNC
Revance Therapeutics, Inc.
RVNC
+$4.65M
4
NTLA icon
Intellia Therapeutics
NTLA
+$4.33M
5
OCUL icon
Ocular Therapeutix
OCUL
+$4.14M

Top Sells

Rank Stock Value
1
SLRN
ACELYRIN
SLRN
+$19.5M
2
IDYA icon
IDEAYA Biosciences
IDYA
+$11.1M
3
BHVN icon
Biohaven
BHVN
+$8.56M
4
ARQT icon
Arcutis Biotherapeutics
ARQT
+$6.33M
5
MRNS
Marinus Pharmaceuticals, Inc
MRNS
+$6.13M

Sector Composition

Rank Sector Weight
1 Healthcare 99.3%
2 Miscellaneous 0.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCVX icon
26
Vaxcyte
PCVX
$9.1B
$5.81M 1.27%
85,000
-5,000
-6% -$346K
NYXH
27
Nyxoah
NYXH
$160M
$4.32M 0.94%
320,000
-24,800
-7% -$283K
SVRA icon
28
Savara
SVRA
$1.13B
$4.26M 0.93%
+855,000
New +$4.13M
SYRS
29
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$4.21M 0.92%
787,545
+428,175
+119% +$2.96M
URGN icon
30
UroGen Pharma
URGN
$2.22B
$4.05M 0.88%
270,000
-50,000
-16% -$817K
NRIX icon
31
Nurix Therapeutics
NRIX
$2.79B
$3.93M 0.86%
+267,210
New +$2.87M
RVNC
32
DELISTED
Revance Therapeutics, Inc.
RVNC
$3.86M 0.84%
+785,000
New +$4.65M
RLMD icon
33
Relmada Therapeutics
RLMD
$482M
$3.53M 0.77%
759,000
-118,000
-13% -$569K
PTGX icon
34
Protagonist Therapeutics
PTGX
$9.67B
$3.26M 0.71%
112,700
– –
ZNTL icon
35
Zentalis Pharmaceuticals
ZNTL
$367M
$3.15M 0.69%
+200,000
New +$2.75M
ALLK
36
DELISTED
Allakos
ALLK
$3.07M 0.67%
+2,435,000
New +$3.78M
GOSS icon
37
Gossamer Bio
GOSS
$83.2M
$2.88M 0.63%
2,440,109
-542,091
-18% -$597K
IBIO icon
38
iBio
IBIO
$69.5M
$2.76M 0.6%
+680,000
New +$855K
VSTM icon
39
Verastem
VSTM
$668M
$2.49M 0.54%
211,400
– –
ALGS icon
40
Aligos Therapeutics
ALGS
$44.1M
$1.6M 0.35%
65,200
+13,320
+26% +$265K
CNTX icon
41
Context Therapeutics
CNTX
$38.2M
$1.53M 0.33%
1,108,357
+133,357
+14% +$150K
PGEN icon
42
Precigen
PGEN
$2.57B
$1.37M 0.3%
947,500
-65,000
-6% -$93.3K
LRMR icon
43
Larimar Therapeutics
LRMR
$421M
$1.32M 0.29%
174,413
-449,087
-72% -$3.5M
FULC icon
44
Fulcrum Therapeutics
FULC
$294M
$1.23M 0.27%
130,000
– –
MOR
45
DELISTED
MorphoSys AG American Depositary Shares
MOR
$1.18M 0.26%
65,000
-80,000
-55% -$1.18M
GKOS icon
46
Glaukos
GKOS
$10.7B
$809K 0.18%
+8,576
New +$766K
PMVP icon
47
PMV Pharmaceuticals
PMVP
$66.3M
$802K 0.17%
+471,481
New +$881K
BDSX icon
48
Biodesix
BDSX
$300M
$765K 0.17%
26,733
+1,908
+8% +$65.3K
RGLS
49
DELISTED
Regulus Therapeutics
RGLS
$490K 0.11%
+170,308
New +$278K
DSGN icon
50
Design Therapeutics
DSGN
$954M
$456K 0.1%
+113,038
New +$302K
1
2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q1 2024 Portfolio in Review

As of Q1 2024, Opaleye Management held 59 positions worth $459M, up 22% from $376M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Opaleye Management withdrew a net $20.4M in Q1 2024, closing 7 positions and reducing 15 holdings. Its most notable exit was IDEAYA Biosciences, an estimated $11.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous.

Against the trend, Opaleye Management opened a new position in Lyell Immunopharma worth $7.48M.

  • Opaleye Management's largest Q1 2024 buy was Lyell Immunopharma: 167,750 shares worth $7.48M.
  • Opaleye Management added most to Intellia Therapeutics in Q1 2024, an estimated $4.33M increase.
  • Opaleye Management's biggest Q1 2024 reduction was ACELYRIN, cutting an estimated $19.5M.
  • Opaleye Management fully exited IDEAYA Biosciences in Q1 2024, selling an estimated $11.1M.
  • Opaleye Management's ten largest holdings make up 57% of its $459M portfolio in Q1 2024.
  • Opaleye Management opened 13 new positions and closed 7 in Q1 2024.
  • Opaleye Management's portfolio value rose 22% quarter-over-quarter to $459M.

Based on Opaleye Management's 13F filing for Q1 2024, filed 15 May 2024.